Bleeding risks with aspirin use for primary prevention in adults: A systematic review for the U.S. preventive services task force

Annals of Internal Medicine

Volumn 164, Issue 12, 2016, Pages 826-835

  Whitlock, Evelyn P ^a   Burda, Brittany U ^b   Williams, Selvi B ^b   Guirguis Blake, Janelle M ^c   Evans, Corinne V ^b  

^a PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE   (United States)

^b CENTER FOR HEALTH RESEARCH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PROTON PUMP INHIBITOR; FIBRINOLYTIC AGENT;

ADULT DISEASE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; DRUG EXPOSURE; FUNDING; HUMAN; INCIDENCE; LOW DRUG DOSE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADULT; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; GASTROINTESTINAL HEMORRHAGE; RISK FACTOR;

ADULT; ASPIRIN; CARDIOVASCULAR DISEASES; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HUMANS; PRIMARY PREVENTION; RISK FACTORS; STROKE;

EID: 84975223728     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-2112     Document Type: Review

References (64)

1. Iwamoto J, Saito Y, Honda A, Matsuzaki Y. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy [Editorial]. World J Gastroenterol. 2013;19:1673-82. [PMID: 23555156] doi: 10.3748/wjg.v19.i11.1673
2. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med.2012;172:209-16.[PMID:22231610]doi: 10.1001/archinternmed.2011.628
3. Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:804-13. doi: 10.7326/M15-2113
4. Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DSM, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:814-25. doi: 10.7326/M15-2117
5. Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms. A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 132. AHRQ Publication No. 13-05193-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015. Accessed at www.ncbi.nlm.nih.gov/books/NBK321643 on 3 March 2016.
6. Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol. 2011;9:762-768.e6. [PMID: 21699808] doi: 10.1016/j.cgh.2011.05.020
7. Valkhoff VE, Sturkenboom MC, Hill C, Veldhuyzen van Zanten S, Kuipers EJ. Low-dose acetylsalicylic acid use and the risk of upper gastrointestinal bleeding: a meta-analysis of randomized clinical trials and observational studies. Can J Gastroenterol. 2013;27:159-67.[PMID: 23516680]
8. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet.2012;379:1602-12. [PMID: 22440946] doi: 10.1016/S0140-6736 (11)61720-0
9. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al; U.S. Preventive Services Task Force. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146:365-75. [PMID: 17339622]
10. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150:405-10. [PMID: 19293073]
11. Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 131. AHRQ Publication No. 13-05195-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015. Accessed at www.ncbi.nlm.nih.gov/pubmedhealth/PMH0079304 on 3 March 2016.
12. Chubak J, Kamineni A, Buist DSM, Anderson ML, Whitlock EP. Aspirin Use for the Prevention of Colorectal Cancer: An Evidence Update for the U.S. Preventive Services Task Force. Evidence Synthesis No. 133. AHRQ Publication No. 15-05228-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
13. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35. [PMID: 11306229]
14. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis 2014. Accessed at www.ohri.ca/programs/clinical-epidemiology/oxford.asp on 21 January 2014.
15. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60. [PMID: 19482214] doi: 10.1016/S0140-6736(09)60503-1
16. Dehmer SP, Maciosek MV, Flottemesch TJ. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: A Decision Analysis. AHRQ Publication No. 15-05229-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015. Accessed at www.ncbi.nlm.nih.gov/books/NBK321651 on 3 March 2016.
17. Fu R, Gartlehner G, Grant M, Shamliyan T, Sedrakyan A, Wilt TJ, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol. 2011;64:1187-97. [PMID: 21477993] doi: 10.1016/j.jclinepi.2010.08.010
18. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351-75. [PMID: 15116347]
19. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. 2009;104:1475-82. [PMID: 19491861] doi: 10.1038/ajg.2009.128
20. de Abajo FJ, Gil MJ, Bryant V, Timoner J, Oliva B, García- Rodríguez LA. Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database. Eur J Clin Pharmacol. 2013;69: 691-701. [PMID: 22955795] doi: 10.1007/s00228-012-1386-3
21. Hreinsson JP, Kalaitzakis E, Gudmundsson S, Bjö rnsson ES. Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting. Scand J Gastroenterol. 2013;48:439-47. [PMID: 23356751] doi: 10.3109/00365521.2012.763174
22. De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286-94. [PMID: 22706834] doi: 10.1001/jama.2012.5034
23. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89-95. [PMID: 11197445]
24. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. [PMID: 9635947]
25. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-41. [PMID: 18997198] doi: 10.1001/jama.2008.623
26. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-35. [PMID: 2664509]
27. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296:313-6. [PMID: 3125882]
28. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al; Prevention of Progression of Arterial Disease and Diabetes Study Group. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. [PMID: 18927173] doi: 10.1136/bmj.a1840
29. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet. 1998;351:233-41. [PMID: 9457092]
30. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841-8. [PMID: 20197530] doi: 10.1001/jama.2010.221
31. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with athero-sclerotic risk factors: a randomized clinical trial. JAMA. 2014;312: 2510-20. [PMID: 25401325] doi: 10.1001/jama.2014.15690
32. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352:1293-304. [PMID: 15753114]
33. Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. A prospective study of aspirin use and the risk of gastrointestinal bleeding in men. PLoS One. 2010;5:e15721. [PMID: 21209949] doi: 10.1371/journal.pone.0015721
34. Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med. 2011; 124:426-33. [PMID: 21531232] doi: 10.1016/j.amjmed.2010.12.022
35. Ekström N, Cederholm J, Zethelius B, Eliasson B, Fhärm E, Rolandsson O, et al. Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register. BMJ Open.2013;3. [PMID: 23604419] doi: 10.1136/bmjopen-2013-002688
36. Iso H, Hennekens CH, Stampfer MJ, Rexrode KM, Colditz GA, Speizer FE, et al. Prospective study of aspirin use and risk of stroke in women. Stroke. 1999;30:1764-71. [PMID: 10471421]
37. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternateday, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77-85. [PMID: 23856681] doi: 10.7326/0003-4819-159-2-201307160-00002
38. Patrono C. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? Eur Heart J. 2013;34:3403-11. [PMID: 23771843] doi: 10.1093/eurheartj/eht058
39. Hernández-Díaz S, Rodríguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol. 2002;55:157-63. [PMID: 11809354]
40. Hernández-Díaz S, García Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22. [PMID: 16987411]
41. Lin KJ, De Caterina R, García Rodríguez LA. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study. Circ Cardiovasc Qual Outcomes. 2014;7:70-7. [PMID: 24254886] doi: 10.1161/CIRCOUTCOMES.113.000494
42. Lanas A, Polo-Tomás M, Casado-Arroyo R. The aspirin cardiovascular/gastrointestinal risk calculator-a tool to aid clinicians in practice. Aliment Pharmacol Ther. 2013;37:738-48. [PMID: 23413984] doi: 10.1111/apt.12240
43. Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10: e0124653. [PMID: 26061035] doi: 10.1371/journal.pone.0124653
44. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55-63. [PMID: 25560714] doi: 10.7326/M14-0697
45. Halvorsen S, Andreotti F, ten Berg JM, Cattaneo M, Coccheri S, Marchioli R, et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol. 2014;64:319-27. [PMID: 25034070] doi: 10.1016/j.jacc.2014.03.049
46. Shiotani A, Kamada T, Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol. 2008;43:581-8. [PMID: 18709479] doi: 10.1007/s00535-008-2206-5
47. Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A, et al; Asociación Española de Gastroenterología. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin nonsteroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731-8. [PMID: 16687434]
48. Hedberg J, Sundström J, Thuresson M, Aarskog P, Oldgren J, Bodegard J. Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding-a cohort study of the effects of proton pump inhibitor use patterns. J Intern Med. 2013;274:371-80. [PMID: 23800296] doi: 10.1111/joim.12103
49. Brotons C, Benamouzig R, Filipiak KJ, Limmroth V, Borghi C. A systematic review of aspirin in primary prevention: is it time for a new approach? Am J Cardiovasc Drugs. 2015;15:113-33. [PMID: 25502483] doi: 10.1007/s40256-014-0100-5
50. van Kruijsdijk RC, Visseren FL, Ridker PM, Dorresteijn JA, Buring JE, van der Graaf Y, et al. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart. 2015;101:369-76. [PMID: 25475110] doi: 10.1136/heartjnl-2014-306342
51. Strate LL. Lower GI bleeding: epidemiology and diagnosis. Gastroenterol Clin North Am. 2005;34:643-64. [PMID: 16303575]
52. Lanas A, García-Rodríguez LA, Polo-Tomás M, Ponce M, Alonso- Abreu I, Perez-Aisa MA, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104:1633-41. [PMID: 19574968] doi: 10.1038/ajg.2009.164
53. Kvasnovsky CL, Papagrigoriadis S, Bjarnason I. Increased diverticular complications with nonsteriodal anti-inflammatory drugs and other medications: a systematic review and meta-analysis. Colorectal Dis. 2014;16:O189-96. [PMID: 24320820] doi: 10.1111/codi.12516
54. ASCEND: A Study of Cardiovascular Events iN Diabetes 2014 [clinical trial]. Accessed at https://clinicaltrials.gov/ct2/show/NCT00135226 on 10 March 2016.
55. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, et al; ACCEPT-D Study Group. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of lowdose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21. [PMID: 17725825]
56. ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36:555-64. [PMID: 24113028] doi: 10.1016/j.cct.2013.09.014
57. A study to assess the efficacy and safety of enteric-coated acetylsalicylic acid in patients with moderate risk for cardiovascular disease (ARRIVE) [clinical trial]. Accessed at http://clinicaltrials.gov/show/NCT00501059 on 8 May 2013.
58. Henderson N, Smith T. Aspirin for the next generation. Ecancermedicalscience. 2013;7:300. [PMID: 23589729] doi: 10.3332/ecancer.2013.300
59. Freedman JE. Appreciating and mitigating bleeding risk. Circulation. 2012;125:e548-50. [PMID: 22492953] doi: 10.1161/CIRCULATIONAHA.112.104224
60. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123:1108-15. [PMID: 21357821] doi: 10.1161/CIRCULATIONAHA.110.973008
61. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64:102-46. [PMID: 22106090] doi: 10.1124/pr.111.004994
62. de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. 2011;28:345-67. [PMID: 21542658] doi: 10.2165/11589340-000000000-00000
63. Dumbleton JS, Avery AJ, Coupland C, Hobbs FD, Kendrick D, Moore MV, et al. The Helicobacter Eradication Aspirin Trial (HEAT): a large simple randomised controlled trial using novel methodology in primary care. EBioMedicine. 2015;2:1200-4. [PMID: 26501118] doi: 10.1016/j.ebiom.2015.07.012
64. Elwood PC, Almonte M, Mustafa M. Is there enough evidence for aspirin in high-risk groups? Curr Colorectal Cancer Reports. 2013;9: 9-16.